ArticleCardiovascular and interventional radiology2026
Efficacy and Safety of Adrenal Artery Embolization for Idiopathic Hyperaldosteronism: A Systematic Review & Meta-Analysis.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of adrenal artery embolization for idiopathic hyperaldosteronism. MATERIALS AND
methodsPubMed, Embase, and Cochrane databases were searched through June 2026. Studies reporting clinical outcomes after adrenal artery embolization for idiopathic hyperaldosteronism were included. Outcomes comprised 24-h ambulatory and home blood pressure, plasma aldosterone and renin, aldosterone-to-renin ratio, serum potassium and cortisol, and safety. Random-effects models and leave-one-out analyses were used.
resultsFour studies including 284 patients allocated to or undergoing adrenal artery embolization were included: outcome-specific sample sizes varied according to data availability. Adrenal artery embolization reduced 24-h systolic blood pressure by 15.31 mmHg and diastolic blood pressure by 10.49 mmHg. Plasma aldosterone decreased by 68.18 pg/mL, the aldosterone-to-renin ratio by 49.03, and serum potassium increased by 0.60 mmol/L. Serum cortisol did not significantly change. Pain and fever occurred in 82.41% (178/216) and 18.98% (41/216) of patients across three studies. Major adverse events occurred in 4.58% (13/284): four strokes (one fatal hemorrhagic, adjudicated unrelated), five hypertensive or severe-hypertension events, one myocardial infarction, one new-onset heart failure, one ventricular tachycardia, and one hypotensive event requiring vasopressors-only three within 1 month.
conclusionAdrenal artery embolization showed preliminary associations with improved blood pressure and biochemical outcomes without a significant change in serum cortisol. Evidence was predominantly uncontrolled, serious adverse events occurred, and superiority over optimized medical therapy was not established. Randomized trials with standardized techniques and long-term clinical outcomes are required. LEVEL OF EVIDENCE: Level IV, Systematic Review/Meta-Analysis of predominantly single-arm studies.
Indexed as
Identifiers
42811134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.